/K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
23 October 2008 - 11:32PM
PR Newswire (US)
Journalists and other readers should disregard the news release
"Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin
Suppository" OTC:ORMP, issued earlier today. The release was
transmitted in error by PR Newswire. DATASOURCE: Oramed
Pharmaceuticals Inc. CONTACT: Company and Investor Relation
Contacts: Oramed Pharmaceuticals, Eric Rosenberg, Cell:
+972-54-566-7713, Office: +972-2-566-0001, Email: ; Media Contacts:
Ruder Finn Israel for Oramed, Matthew Krieger, Cell:
+972-54-467-6950, Office: +972-2-589-2003, Email:
Copyright